CU Anschutz–Led Team Publishes National Roadmap for First Approved Immunotherapy for ...

The FDA expanded approval of teplizumab, the first immunotherapy for children aged 8 to 17 newly diagnosed with type 1 diabetes, to slow autoimmune destruction of insulin-producing cells. A national expert team led by University of Colorado Anschutz published practical guidance to integrate this treatment into care within eight weeks of diagnosis.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 11 Nov 2026 and 12 Nov 2026.